听力与言语-语言病理学

行为科学

医学伦理学

你正在浏览EXPERT OPINION ON PHARMACOTHERAPY期刊下所有文献
  • Advances in pharmacotherapy of vestibular and ocular motor disorders.

    abstract:INTRODUCTION:Vertigo and dizziness are common chief complaints of vestibular and ocular motor disorders (lifetime prevalence 30%). Treatment relies on physical, pharmacological, psychological and rarely surgical approaches. Eight groups of drugs are currently used in vestibular and ocular motor disorders, namely anti-v...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1610386

    authors: Zwergal A,Strupp M,Brandt T

    更新日期:2019-07-01 00:00:00

  • Treatment of classical Hodgkin's lymphoma in children and adolescents.

    abstract:INTRODUCTION:The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5 years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different chemotherapy schem...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1606212

    authors: Gómez-Almaguer D,González-Llano O,Jiménez-Antolinez V,Gómez-De León A

    更新日期:2019-07-01 00:00:00

  • The pharmacologic management of multiple myeloma in older adults.

    abstract:INTRODUCTION:Multiple myeloma is a disease predominately affecting older adults. Pivotal to treating older adults is understanding their physiologic differences compared to younger subjects and how the complexity of therapies has an impact upon this patient population. AREAS COVERED:Herein, the authors address the eff...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1577822

    authors: Dempsey JL,Johns A,Rosko AE,Lazarus HM

    更新日期:2019-05-01 00:00:00

  • Pharmacotherapy for the treatment of vaginal atrophy.

    abstract:INTRODUCTION:Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low dose estrogen product is the main th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1574752

    authors: Donders GGG,Ruban K,Bellen G,Grinceviciene S

    更新日期:2019-05-01 00:00:00

  • Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.

    abstract:INTRODUCTION:Obesity is a growing health problem that has numerous comorbidities, including cardiovascular disease (CVD). The multi-disciplinary treatment of obesity now includes the use of pharmacotherapy. When treating patients with obesity and CVD, certain medications may be more appropriate than others. AREAS COVE...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1561867

    authors: Andrew CA,Saunders KH,Shukla AP,Aronne LJ

    更新日期:2019-04-01 00:00:00

  • Advances in orally administered pharmacotherapy for the treatment of migraine.

    abstract:INTRODUCTION:Migraine is a common and highly disabling neurological disorder whose acute treatment remains problematic and unsatisfactory in a high percentage of cases. Consequently, there remains a need for new symptomatic therapies that can be easily handled by patients (i.e. by oral administration). AREAS COVERED:T...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1549223

    authors: Martelletti P,Giamberardino MA

    更新日期:2019-02-01 00:00:00

  • Current therapeutical strategies for allergic rhinitis.

    abstract:INTRODUCTION:Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option. AREAS COVERED:This review focuses...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1543401

    authors: Klimek L,Sperl A,Becker S,Mösges R,Tomazic PV

    更新日期:2019-01-01 00:00:00

  • Brimonidine tartrate for the treatment of glaucoma.

    abstract:INTRODUCTION:Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1544241

    authors: Oh DJ,Chen JL,Vajaranant TS,Dikopf MS

    更新日期:2019-01-01 00:00:00

  • Pharmacotherapy for the prevention of malaria in pregnant women: currently available drugs and challenges.

    abstract:INTRODUCTION:Malaria in pregnancy continues to be a significant public health burden globally, with over 100 million women at risk each year. Sulfadoxine-pyrimethamine (SP) is the only antimalarial recommended for intermittent preventive therapy in pregnancy (IPTp) but increasing parasite resistance threatens its viabi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1526923

    authors: Moore BR,Davis TME

    更新日期:2018-11-01 00:00:00

  • Clinical review of Clostridium difficile infection: an update on treatment and prevention.

    abstract:INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524872

    authors: Daniels LM,Kufel WD

    更新日期:2018-11-01 00:00:00

  • Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.

    abstract:INTRODUCTION:Only 40-60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of pati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1528230

    authors: Grassi G,Pallanti S

    更新日期:2018-10-01 00:00:00

  • Pharmacological management of depression in patients with multiple sclerosis.

    abstract:INTRODUCTION:The pharmacotherapeutic management of depression in patients with multiple sclerosis (MS) is a matter of debate that cannot be decided from the evidence available in the current literature. Therefore, its management essentially relies on the clinical experience of the prescribing clinician rather than on e...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1516207

    authors: Carta MG,Paribello P,Anastasia A,De Berardis D,Nardi AE,Fornaro M

    更新日期:2018-10-01 00:00:00

  • On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524874

    authors: Samples LS,Graf SA

    更新日期:2018-10-01 00:00:00

  • Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.

    abstract:INTRODUCTION:Meropenem-vaborbactam is a new beta-lactam/beta-lactamase inhibitor combination that combines a carbapenem antibiotic with a first-in-class, boronic acid pharmacophore, serine beta-lactamase inhibitor which has potent inhibitory activity against class A carbapenemases, especially Klebsiella pneumoniae carb...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1512586

    authors: Wu G,Cheon E

    更新日期:2018-09-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.

    abstract:BACKGROUND:This study aimed to analyze the characteristics and outcomes of patients suffering from non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor mutations (EGFRm+) receiving gefitinib who remained clinically stable following confirmation of progressive disease (PD) using Response Evaluation C...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1484903

    authors: Hosomi Y,Tanai C,Yoh K,Goto Y,Sakai H,Kato T,Kaburagi T,Nishio M,Kim YH,Inoue A,Hasegawa Y,Isobe H,Tomizawa Y,Mori Y,Minato K,Yamada K,Ohashi Y,Kunitoh H

    更新日期:2018-07-01 00:00:00

  • Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

    abstract:INTRODUCTION:Treating acute myeloid leukemia (AML) in older adults remains daunting. The unique biology often renders conventional chemotherapies less effective. Accurately predicting the toxicities of treatment is another unresolved challenge. Treatment planning thus requires a good knowledge of the current trial data...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1465562

    authors: Michaelis LC,Klepin HD,Walter RB

    更新日期:2018-06-01 00:00:00

  • Oral chemotherapy for the treatment of hepatocellular carcinoma.

    abstract:INTRODUCTION:Many clinical trials have been conducted with chemotherapies in patients with advanced hepatocellular carcinoma (HCC). However, few agents have shown efficacy. It is thought that the efficacy of some agents might have resulted from the heterogeneity of tumors, insufficient dosages due to liver cirrhosis, a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1479398

    authors: Yamamoto S,Kondo S

    更新日期:2018-06-01 00:00:00

  • Non-insulin pharmacological therapies for treating type 1 diabetes.

    abstract:INTRODUCTION:Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of int...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1483339

    authors: Frandsen CS,Dejgaard TF,Madsbad S,Holst JJ

    更新日期:2018-06-01 00:00:00

  • Pharmacotherapeutic strategies for treating hypertension in patients with obesity.

    abstract:INTRODUCTION:Hypertension and obesity are important health challenges that independently increase cardiovascular morbidity and mortality. There is a lack of randomized controlled trials to clearly inform on preferred drug choices to be adopted in clinical practice for the treatment of obesity-related hypertension (OHT)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1458092

    authors: Carnagarin R,Matthews V,Gregory C,Schlaich MP

    更新日期:2018-05-01 00:00:00

  • Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.

    abstract:INTRODUCTION:Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease has been revolutionized. Therapy has transformed over the last several years with the approval of second generation direct acting antivirals, and currently utilized medications for the treat...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1459567

    authors: Cory TJ,Mu Y,Gong Y,Kodidela S,Kumar S

    更新日期:2018-05-01 00:00:00

  • A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.

    abstract:BACKGROUND:This comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic STROke (PRASTRO)-I trial investigates the noninferiority of prasugrel to clopidogrel sulfate in the prevention of recurrence of primary events (ischemic stroke, myocardial infarction, and death from other vascular causes), and th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/14656566.2018.1444029

    authors: Nagao T,Toyoda K,Kitagawa K,Kitazono T,Yamagami H,Uchiyama S,Tanahashi N,Matsumoto M,Minematsu K,Nagata I,Nishikawa M,Nanto S,Abe K,Ikeda Y,Ogawa A

    更新日期:2018-04-01 00:00:00

  • Pharmacotherapy of retinal disease with visual cycle modulators.

    abstract:INTRODUCTION:Pharmacotherapy with visual cycle modulators (VCMs) is under investigation for retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt macular dystrophy (SMD) and nonexudative age-related macular degeneration (AMD), all blinding diseases that lack effective treatment options. AREAS COVERED:...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1448060

    authors: Hussain RM,Gregori NZ,Ciulla TA,Lam BL

    更新日期:2018-04-01 00:00:00

  • Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.

    abstract:BACKGROUND:This subgroup analysis of STELLA-LONG TERM interim data explored the long-term safety and efficacy of ipragliflozin in non-elderly vs. elderly Japanese type 2 diabetes mellitus (T2DM) patients. RESEARCH DESIGN AND METHODS:STELLA-LONG TERM is an ongoing 3-year prospective surveillance study of Japanese T2DM ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1434145

    authors: Maegawa H,Tobe K,Tabuchi H,Nakamura I,Uno S

    更新日期:2018-03-01 00:00:00

  • Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.

    abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous system affecting both white matter and grey matter in the earliest phases of its course. The crucial role of neurodegeneration in disability progression in MS, regardless of white matter damage, has been confirm...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1434143

    authors: Pitteri M,Magliozzi R,Bajrami A,Camera V,Calabrese M

    更新日期:2018-03-01 00:00:00

  • Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.

    abstract::The recently published results of the sequential treatment of postmenopausal osteoporotic women with subcutaneous abaloparatide (80 µg/day) (ABL) for 18 months followed by 6 months of oral alendronate (70 mg/week) (ALN) support the administration of an anti-resorptive agent after completion of a treatment course with ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2017.1418857

    authors: Reginster JY,Al Daghri N,Kaufman JM,Bruyère O

    更新日期:2018-02-01 00:00:00

  • An overview of pharmacotherapy for bipolar I disorder.

    abstract:INTRODUCTION:Bipolar I disorder (BD I) is complex with a chronic course that significantly impacts a sufferer's quality of life. As of right now, there are many available treatments that aim to rapidly treat manic or depressive episodes and stabilize mood. The purpose of this report is to provide an up-to-date comprehe...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1426746

    authors: Morsel AM,Morrens M,Sabbe B

    更新日期:2018-02-01 00:00:00

  • Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

    abstract:INTRODUCTION:Breast cancer (BC) remains the most frequently diagnosed cancer and the most common cause of cancer death among women of all races worldwide. Over 80% of BC cases are hormone receptor (HR)-positive, comprised of luminal A and luminal B per molecular subtypes, imposing an urgent need to fully understand the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1429407

    authors: Duso BA,Trapani D,Viale G,Criscitiello C,D'Amico P,Belli C,Mazzarella L,Locatelli M,Minchella I,Curigliano G

    更新日期:2018-02-01 00:00:00

  • Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.

    abstract:AIM:To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS:The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14656566.2017.1400011

    authors: Cai X,Gao X,Yang W,Ji L

    更新日期:2017-12-01 00:00:00

  • Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.

    abstract::The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2017.1395021

    authors: Reginster JY,Al Daghri NM,Bruyere O

    更新日期:2017-12-01 00:00:00

  • Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.

    abstract:BACKGROUND:This study investigated the safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin (100 mg/day) and low-dose metformin (500 or 750 mg/day). RESEARCH DESIGN AND METHODS:Fifty patients were randomly allocated to the control group (maintaining...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2017.1404576

    authors: Suzuki L,Kanazawa A,Uzawa H,Osonoi Y,Masuyama A,Azuma K,Takeno K,Takayanagi N,Sato J,Someya Y,Komiya K,Goto H,Mita T,Ikeda F,Ogihara T,Shimizu T,Ohmura C,Saito M,Osonoi T,Watada H

    更新日期:2017-12-01 00:00:00

  • AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives.

    abstract:INTRODUCTION:The alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors are the major mediators of glutamate-mediated excitatory neurotransmission, and are critical for synchronization and spread of epileptic activity. Areas covered: AMPA receptor antagonists have been also developed as antiepilepti...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1392509

    authors: Di Bonaventura C,Labate A,Maschio M,Meletti S,Russo E

    更新日期:2017-11-01 00:00:00

  • An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

    abstract:INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1378346

    authors: Raoul JL,Gilabert M,Adhoute X,Edeline J

    更新日期:2017-10-01 00:00:00

  • The role of Cediranib in ovarian cancer.

    abstract:INTRODUCTION:Treatment options for relapsed ovarian cancer have increased over the decade with the addition of targeted agents, such as PARP inhibitors and antiangiogenic agents. Bevacizumab, a monoclonal antibody binding vascular endothelial growth factor (VEGF), was the first anti-angiogenic agent to be incorporated ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1383384

    authors: Orbegoso C,Marquina G,George A,Banerjee S

    更新日期:2017-10-01 00:00:00

  • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.

    abstract:INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369956

    authors: Flynn MJ,Larkin JMG

    更新日期:2017-10-01 00:00:00

  • Second line treatment options for pancreatic cancer.

    abstract:INTRODUCTION:Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase II...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369955

    authors: Passero FC Jr,Saif MW

    更新日期:2017-10-01 00:00:00

  • Medical management for neurosurgical related seizures.

    abstract:INTRODUCTION:Seizures or chronic epilepsy are a relatively common occurrence in a neurosurgical setting. However, seizure treatment after neurosurgery has received less attention compared with other causes and only few data are availaible in the literature on management in neurosurgical patients. Areas covered: This pa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1373092

    authors: Ambrosi M,Orsini A,Verrotti A,Striano P

    更新日期:2017-10-01 00:00:00

  • Efficacy of elagolix in the treatment of endometriosis.

    abstract:INTRODUCTION:Much research has gone into developing medications that can be used to alleviate endometriosis-associated symptoms. In addition to already established medications, a new GnRH antagonist, elagolix, is in development. The novelty of this drug compared to other GnRH antagonists, is its nonpeptide structure, a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1359258

    authors: Perricos A,Wenzl R

    更新日期:2017-09-01 00:00:00

  • Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

    abstract:INTRODUCTION:The introduction of novel agents has significantly improved multiple myeloma (MM) patient outcome during the last two decades. MM received the most drug approvals for any one malignancy during this time period, both in the United States as well as in Europe. Areas covered: Proteasome inhibitors, immunomodu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1340942

    authors: Podar K,Pecherstorfer M

    更新日期:2017-08-01 00:00:00

  • Novel therapy for childhood acute lymphoblastic leukemia.

    abstract:INTRODUCTION:During recent decades, the prognosis of childhood acute lymphoblastic leukemia (ALL) has improved dramatically, nowadays, reaching a cure rate of almost 90%. These results are due to a better management and combination of old therapies, refined risk-group stratification and emergence of minimal residual di...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1340938

    authors: Santiago R,Vairy S,Sinnett D,Krajinovic M,Bittencourt H

    更新日期:2017-08-01 00:00:00

454 条记录 2/12 页 « 12345678...1112 »